

*AMENDMENTS TO THE CLAIMS*

This listing of claims replaces all prior versions, and listings, of claims in the application.

1. (Currently Amended) An isolated nucleic acid molecule comprising a polynucleotide selected from a the group consisting of:

~~(a) a polynucleotide encoding amino acids from about 1 to about 108 of the amino acid sequence contained in SEQ ID NO:2;~~

~~(b) (a) a polynucleotide encoding amino acids from about 2 to about 108 of the amino acid sequence contained in SEQ ID NO:2; and~~

~~(c) the polynucleotide complement of the polynucleotide of (a) or (b); and~~

~~(d) a polynucleotide at least 90% identical to the polynucleotide of (a), (b) or (c).~~

2. (Canceled)

3. (Canceled)

4. (Canceled)

5. (Canceled)

6. (Canceled)

7. (Original) The isolated nucleic acid molecule of claim 1, which is DNA.

8. (Previously Presented) A recombinant vector comprising the nucleic acid molecule of claim 1 and a vector in operable linkage to a promoter.

9. (Canceled)

10. (Currently Amended) A recombinant host cell comprising the recombinant vector of claim 8 ~~and a host cell.~~

11-35. (Canceled)

36. (Currently Amended) An agent that inhibits the expression of the polypeptide of claim 1 ~~143~~ in a cell, wherein the agent is ~~selected from a group consisting of~~ an antisense oligonucleotides ~~and ribozymes.~~

37. (Canceled)

38. (Previously Presented) The agent of claim 36, which is an antisense oligonucleotide having a phosphodiester backbone or modified base composition.

39. (Canceled)

40. (Withdrawn) The agent of claim 36, wherein the agent is contained in a liposomal formulation.

41. (Canceled)

42. (Previously Presented) The agent of claim 38, wherein the agent is contained in a liposomal formulation.

43. (Canceled)

44. (Withdrawn) A method of inhibiting apoptosis or proliferation of cancer cell, comprising inhibiting expression of SCC-S2 in said cell by transforming the cell with the vector of claim 8.

45-54. (Canceled)